Retrophin Reports First Quarter 2019 Financial Results
May 07, 2019 16:01 ET
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN Continued...
Retrophin to Report First Quarter 2019 Financial Results
April 23, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, April 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S....
Retrophin to Present at Upcoming Investor Conferences
March 05, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor...
Retrophin Provides Corporate Update and 2019 Outlook
January 07, 2019 07:00 ET
|
Retrophin, Inc.
SAN DIEGO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the...
Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare...
Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference
November 28, 2018 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO 2018 Prescriptions for Success...
Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
November 12, 2018 07:00 ET
|
Retrophin, Inc.
PDUFA date set for June 30, 2019 SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Retrophin to Present at the Jefferies 2018 London Healthcare Conference
November 07, 2018 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare...
Robbins Arroyo LLP: Retrophin, Inc. (RTRX) Misled Shareholders According to a Recently Filed Class Action
October 22, 2014 19:16 ET
|
Robbins LLP
SAN DIEGO and NEW YORK, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Retrophin, Inc. (Nasdaq:RTRX) has filed a federal securities...